Algorae Pharmaceuticals Limited
1AI
株式のランク
#30945
Algorae Pharmaceuticals Limited, a company established in 1987 and based in... Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.
株価
$0.00705285
時価総額
$14.30M
変化（1日）
0.00%
変化（1年）
-30.71%
国
AU
取引 Algorae Pharmaceuticals Limited (1AI)
カテゴリー
Healthcare
の時価総額 Algorae Pharmaceuticals Limited(1AI)
時価総額: $14.30M
October 2026時点で、Algorae Pharmaceuticals Limited の時価総額は $14.30M です。これは、当社のデータによると、Algorae Pharmaceuticals Limited が世界で30945th番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Algorae Pharmaceuticals Limited の時価総額の履歴（2004 から 2026 まで）
